[go: up one dir, main page]

PE20212270A1 - Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas - Google Patents

Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas

Info

Publication number
PE20212270A1
PE20212270A1 PE2021001490A PE2021001490A PE20212270A1 PE 20212270 A1 PE20212270 A1 PE 20212270A1 PE 2021001490 A PE2021001490 A PE 2021001490A PE 2021001490 A PE2021001490 A PE 2021001490A PE 20212270 A1 PE20212270 A1 PE 20212270A1
Authority
PE
Peru
Prior art keywords
compound
formulations
enhanced bioavailability
fluoro
refers
Prior art date
Application number
PE2021001490A
Other languages
English (en)
Inventor
Akm Nasir Uddin
Mandar Vasant Dali
Onkar Shripad Vaze
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of PE20212270A1 publication Critical patent/PE20212270A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA AMORFA DEL COMPUESTO 5-FLUORO-2-(6-FLUORO-2-METIL-1H-BENCIMIDAZOL-1-IL)-N-[4-(TRIFLUOROMETIL)FENIL]PIRIMIDIN-4,6-DIAMINA DENOMINADO COMPUESTO A. TAMBIEN SE REFIERE A UNA DISPERSION SOLIDA AMORFA QUE COMPRENDE LA FORMA AMORFA DEL COMPUESTO A Y UN POLIMERO ESTABILIZANTE TAL COMO POLIVINILPIRROLIDONA O ACETATO SUCCINATO DE HIDROXIPROPILMETILCELULOSA, DONDE LA CANTIDAD EN PESO DEL COMPUESTO A Y LA CANTIDAD EN PESO DEL POLIMERO ESTABILIZANTE ESTA EN UN INTERVALO DE ENTRE 10:90 Y 40:60.
PE2021001490A 2019-03-11 2020-03-09 Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas PE20212270A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962816402P 2019-03-11 2019-03-11
PCT/US2020/021648 WO2020185648A1 (en) 2019-03-11 2020-03-09 Compound form having enhanced bioavailability and formulations thereof

Publications (1)

Publication Number Publication Date
PE20212270A1 true PE20212270A1 (es) 2021-11-30

Family

ID=70166162

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001490A PE20212270A1 (es) 2019-03-11 2020-03-09 Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas

Country Status (20)

Country Link
US (1) US20220185795A1 (es)
EP (1) EP3938368B1 (es)
JP (1) JP2022524424A (es)
KR (1) KR20210151061A (es)
CN (1) CN113853374B (es)
AU (1) AU2020235825A1 (es)
BR (1) BR112021017353A2 (es)
CA (1) CA3131801A1 (es)
CL (1) CL2021002365A1 (es)
CO (1) CO2021011836A2 (es)
EA (1) EA202192167A1 (es)
EC (1) ECSP21067104A (es)
HU (1) HUE062796T2 (es)
IL (1) IL286163A (es)
MX (1) MX2021010906A (es)
PE (1) PE20212270A1 (es)
PL (1) PL3938368T3 (es)
SG (1) SG11202109503TA (es)
WO (1) WO2020185648A1 (es)
ZA (1) ZA202106437B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104918919A (zh) * 2012-11-21 2015-09-16 Ptc医疗公司 取代的反向嘧啶Bmi-1抑制剂
EP3836932A2 (en) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
CA3131249A1 (en) * 2019-02-28 2020-09-03 Ptc Therapeutics, Inc. 5-fluoro-2-(6fluoro-2-methyl-1h-benzo(d)imidazol-1-yl)-n4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine dor treating a multiple myeloma
JP7602481B2 (ja) * 2019-03-27 2024-12-18 ピーティーシー セラピューティクス， インコーポレイテッド 肉腫を治療する方法に有用な組み合わせ
EP4065090A1 (en) * 2019-11-26 2022-10-05 Ikena Oncology, Inc. Ahr inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104918919A (zh) 2012-11-21 2015-09-16 Ptc医疗公司 取代的反向嘧啶Bmi-1抑制剂
UA116004C2 (uk) * 2013-01-22 2018-01-25 Ф. Хоффманн-Ля Рош Аг Фармацевтична композиція з покращеною біодоступністю
JP6878398B2 (ja) * 2015-04-03 2021-05-26 インパクト セラピューティクス インコーポレイティドＩｍｐａｃｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ Ｐａｒｐ阻害剤固形医薬剤型及びその使用
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide

Also Published As

Publication number Publication date
WO2020185648A1 (en) 2020-09-17
EP3938368A1 (en) 2022-01-19
AU2020235825A1 (en) 2021-09-30
JP2022524424A (ja) 2022-05-02
ZA202106437B (en) 2025-01-29
ECSP21067104A (es) 2021-11-18
US20220185795A1 (en) 2022-06-16
HUE062796T2 (hu) 2023-12-28
SG11202109503TA (en) 2021-09-29
BR112021017353A2 (pt) 2021-11-16
IL286163A (en) 2021-10-31
CA3131801A1 (en) 2020-09-17
KR20210151061A (ko) 2021-12-13
CN113853374B (zh) 2025-02-28
EA202192167A1 (ru) 2022-01-12
EP3938368B1 (en) 2023-06-07
CN113853374A (zh) 2021-12-28
PL3938368T3 (pl) 2023-12-27
CO2021011836A2 (es) 2021-12-10
MX2021010906A (es) 2021-10-01
CL2021002365A1 (es) 2022-04-22

Similar Documents

Publication Publication Date Title
PE20212270A1 (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
GEAP202215671A (en) Microbiocidal thiazole derivatives
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
GEAP202215378A (en) Microbiocidal thiazole derivatives
PE20170662A1 (es) Compuestos de aminopiridiloxipirazol
TWD192468S (zh) 真空吸塵器（三十九）
TWD192692S (zh) 真空吸塵器（五十三）
TWD192465S (zh) 真空吸塵器（九）
EA201892734A1 (ru) ПРОИЗВОДНЫЕ АЗАБЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ pI3K BETA
JOP20200024A1 (ar) مركبات ثنائي هيدروكساديازينون
MX2014004070A (es) Composiciones para el cuidado del pelo y metodos para su uso.
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου
MX2022001161A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos.
UY36054A (es) “CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENOPIRIDOPIRAZINADIONAS NOVEDOSAS”.
MX2019007571A (es) Polimorfos.
TR201910573T4 (tr) Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
UY36257A (es) “compuestos de imidazopiridazina”.
AR110249A1 (es) Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
EA201500375A1 (ru) Композиция для ухода за ротовой полостью
MX2019010695A (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
CO2018007663A2 (es) Compuestos indolinonas y su uso en el tratamiento de enfermedades fibróticas
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
CL2018003610A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina.
UY36546A (es) “ciclopropabenzofuranil-piridopirazindionas novedosas”.